Clinically Proven Reduction of Nasal Bacteria

Nozin Research

The American Journal of Infection Control (AJIC) has published the article: “Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic”

This important study demonstrated that Nozin Nasal Sanitizer® antiseptic decreased Staph aureus and total bacterial carriage, ” suggesting the usefulness of this approach as a safe, effective and convenient alternative to antibiotic treatment.” The clinical study was conducted at the Medical University of South Carolina (MUSC). The Nozin study record detail is listed at clinicaltrials. gov, a web based resource on clinical studies maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).

For more information see discussion on the import of the MUSC study on nozinpro.com. A poster on the Nozin study was presented by a primary researcher at the ID Week infectious disease conference.

At the IDSA annual meetingID Week 2016, Baylor Orthopedic and Spine Hospital at Arlington presented results of a study entitled: Pre- and Post-Operative Participation of Orthopedic Patients and Surgical Staff in a Novel Intervention to Reduce Staphylococcus aureus Infection. This is the IDWeek link to the abstract on the Baylor study on the perioperative use of Nozin® Nasal Sanitizer® by surgical patients and surgical staff.  For this 9 month Baylor study: “The inclusion of alcohol-based nasal antiseptic use by both surgical patients and staff in IC protocols during the peri-operative period resulted in a marked decrease in SSIR.” The antiseptic utilized was Nozin® Nasal Sanitizer®. The study summary stated: “The addition of nasal antiseptic to our standard procedures for reducing skin carriage resulted in a marked and significant decrease in S. aureus SSIs.”

At the APIC 2016 annual meeting Nina Deatherage, RN, BSN, PHN, CIC, Lead Infection Preventionist at Marshall Medical Center, Placerville, CA, presented the abstract “Impact of Reduced Isolation and Contact Precaution Procedures on Infection Rates and Facility Costs at a Non-profit Acute Care Hospital.“ Her research concluded: “Elimination of CP [Contact Precautions] in MRSA non-infected patients while maintaining low infection rates and improving staff and patient satisfaction was achieved with IC protocols utilizing nasal and skin decolonization. A significant reduction in CP-related PPE costs also resulted.” In this study, Nozin® Nasal Sanitizer® antiseptic was selected to achieve nasal decolonization.

Contributing Labs

Extensive studies were undertaken to demonstrate that Nozin® Nasal Sanitizer® antiseptic is a safe, highly effective anti-microbial that provides long lasting action to help reduce the risk of infection. Nozin research shows a clinically proven reduction of nasal bacteria. These studies were conducted at leading independent US testing centers specializing in antimicrobial and personal care product testing with results interpretation.  All studies are statistically designed using Good Laboratory Practices (GLPs) to ensure FDA/EPA regulatory compliance and market success. The following are some test results.

Nasal Sanitizer® kills microbes in lab tests

Summary: In laboratory tests conducted at several leading, FDA recognized testing facilities, and under GLP testing protocols, Nozin® Nasal Sanitizer® antiseptic was effective in killing at least 99.99% of bacterial pathogens such as staph aureus, strep pneumoniae, strep pyogenes, mycobacterium smegmatis, and 99.9% of various pathogenic virus including rhinovirus type-14 (often responsible for the common cold), human coronavirus (responsible for the deadly SARS outbreak) and influenza type-A (influenza contracted by humans and birds).

Summary: While it is difficult to simulate the varied conditions of the human nose in an in-vitro model, there are surrogate tests that have been developed to help simulate these conditions. One such surrogate study is the use of a biofilm to help model in-vivo conditions.

This study examined the ability of Nasal Sanitizer® antiseptic to inhibit the growth of bacteria in biofilms over a period of up to 8 hours. Staphylococcus aureus, the challenge strain selected for the experiment and a pathogen commonly found to colonize the nares of healthcare personnel, was challenged with four test materials.

Results: Compared to control treatments, Nozin® Nasal Sanitizer® antiseptic substantially reduced the bacterial growth even in the protective environment of the biofilm.

Nozin Nasal Sanitizer® is shown to control bacteria for hours in human subjects

Summary: The effect of Nozin® Nasal Sanitizer® antiseptic on the growth of bacteria in the nose was tested by applying Nasal Sanitizer® or a control reagent to the noses of 30 subjects. The number of bacteria recovered from the nose was then determined over a 12 hour period following application. The number of bacteria recovered from the group treated with Nasal Sanitizer® antiseptic was reduced by 90% compared to the control-treated group.

Results: Nozin Nasal Sanitizer® inhibits bacteria growth in the nose up to 12 hours.

Nozin Nasal Sanitizer® safe in dermal toxicity, skin irritation study

Summary: Nozin Nasal Sanitizer® antiseptic was tested in human subjects to determine whether it could induce direct toxic effects to the skin or whether it could stimulate the development of allergic responses.  To determine safety,  Nasal Sanitizer® antiseptic was applied to a single location on the skin of the subjects once daily for 21 days.  Evidence of Inflammation and irritation was compared between application of Nasal Sanitizer® and a 0.1% solution of Sodium Lauryl Sulfate, a common ingredient in soaps, shampoos, and other skin and hair care products.  After a rest period of 2 weeks, Nasal Sanitizer® antiseptic was reapplied to see if an allergic response had developed. 

Results: Compared to the commonly used Sodium Lauryl Sulfate, there was no evidence of toxicity or allergic responses induced by Nasal Sanitizer® antiseptic. Subjects did not become sensitized to Nasal Sanitizer® and none of the subjects experienced an increase in skin irritation up to seventy-two (72) hours following the challenge exposure of three (3) weeks.

Conclusion: Nozin Research helps define Benefits of Nozin Nasal Sanitizer®

Better health and enhanced lifestyle can be key benefits of adopting a sound hygienic routine. Top physicians and scientists realize that the hygienic benefits Nasal Sanitizer® antiseptic offers could provide critical first line defense in high risk, crowded or confined areas (e.g. hospitals, airplanes, offices, schools, etc). Nasal Sanitizer® can help reduce risk as an important part of health maintenance and infection control.

Contact your Nozin representative.

Email: info@nozin.com

Call toll free: 1-877-NOZIN4U
or 1-877-669-4648

Office line: 1-301-337-2059
or 1-877-669-4648

Web: Nozin.com Nozinpro.com

Mail:
Nozin
P.O. Box 70663
Chevy Chase, MD 20813

Defense that makes sense®

In the past decade, hand sanitizers have become recognized and popularly used to deter microbial transmission. Because hand-to-nose contact is an important mechanism for transmission, it can be beneficial to sanitize the skin on the nose as well as on the hands.

Nasal Sanitizer® antiseptic is specially formulated for the vulnerable and sensitive skin at the distal area of the nose (nasal vestibule) and helps control germ populations that come to reside there. Lab tests show that Nasal Sanitizer® kills pathogens. Human trial results show that one application of Nasal Sanitizer® antiseptic can be effective for over eight hours.

Nozin® Nasal Sanitizer®Nasal Sanitizer®  is unique in that its antimicrobial action occurs at the nose where many pathogens come to reside and may escape routine hygiene. The Center for Disease Control (CDC) already heavily promotes the importance of frequent hand washing and of hand sanitizers in helping prevent germs residing on hands from being transmitted to the nose. Nasal Sanitizer® antiseptic is longer lasting than many hand sanitizers and directly targets a critical area of infection, the nose. Nasal Sanitizer® adds a targeted, long-acting level of defense by helping to shield your nose from hand-borne or airborne germs. Regular use of Nasal Sanitizer® antiseptic in conjunction with hand washing could provide a very effective hygienic regimen which can help reduce the risk of infection.

Many top physicians and scientists realize the compelling logic of hygienic innovation that Nozin offers.  Nozin® Nasal Sanitizer® antiseptic is a professionally valued and sensible approach to aid in prevention.


© 2004-2017 Global Life Technologies Corp. All rights reserved. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease.